1 Jan 2025
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
Objective: To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVpreF) to protect infants against severe RSV-associated illness.
Epub 2025 Jan 2.
DOI: 10.1097/AOG.0000000000005817
Useful Resources
Related Articles
-
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
BY Eric A F Simões et al -
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
BY Beate Kampmann et al -
How Can We Accelerate Maternal Vaccination Globally?
BY Kate Fay, Michelle J Groome, Hellen Barsosio, Anna C Seale -
Bridging the gap to malaria vaccination in Africa: Challenges and opportunities
BY Olalekan John Okesanya et al -
Epidemiological evaluation of vaccines: efficacy, safety and policy (Short Course)
BY GHN_editors
Please Sign in (or Register) to view further.